Cancer specialists, gathered for an annual meeting, are reporting progress in the fight against lung cancer, the most common and deadliest form of cancer, but little progress in treating colorectal cancer.
Doctors and researchers at the 45th gathering of the American Society of Clinical Oncology (ASCO) — the world’s main cancer conference — on Saturday learned of two studies showing progress in the battle against lung cancer.
The first study showed how the combination of two anti-cancer treatments following standard chemotherapy can slow the advance of lung cancer.
Patients treated with a combination of Tarceva, sold by the Swiss drugmaker Roche, and Avastin, a drug by Roche’s Genentech unit, saw their cancer growth slow more than a control group treated with Avastin.
More than 750 patients were randomized to receive Avastin and a placebo, or Avastin and Tarceva. Those in the Tarceva group survived an average of 4.8 months before the cancer started growing again, compared to 3.7 months for the control group, said Vincent Miller, the study’s main author.
That translates to a 29 percent reduced risk of disease progression for patients who took a combination of Tarceva and Avastin.
“This is the first study to show that adding erlotinib [Tarceva] to maintenance therapy with bevacizumab [Avastin] delays disease progression in patients who have already received bevacizumab as part of their initial chemotherapy,” Miller said.
A second study with 663 patients with advance lung cancer were given the drug Alimta, from the US’ Eli Lilly, which blocks cell growth.
Preliminary results showed that patients who took the drug lived 26 percent longer compared with a control group that took a placebo: 13.4 months against 10.6 months.
As in the first study, all the patients had already received four standard chemotherapy sessions.
“This study will change the overall standard of care,” said Chandra Belani, the deputy director of the Penn State Cancer Institute, as she presented the research.
“Maintenance therapy with Alimta [permetrexed] offers a new paradigm for patients who have advanced lung cancer, because it has a low toxicity and can be given on an ongoing basis over a prolonged period of time to extend patients’ lives,” she said.
However there were few advances to report in the fight against colorectal cancer, the second deadliest type of cancer.
Research on 2,710 patients with Phase Three colorectal cancer taking the drug Avastine along with standard chemotherapy showed no difference in the survival rate or the recurrence of the tumor after three-and-a-half years when compared to those not taking the drug.
Another study conducted in Italy among 747 patients with advanced colorectal cancer showed that the drug Eloxatine from the French firm Sanofi did not reduce the size of the tumor when combined with standard treatment used ahead of cancer surgery.
Meanwhile, hormonal therapy for menopause, already linked to an increase in breast cancer and strokes, also strongly increases the risk of death among women who develop lung cancer, research showed.
The findings are based on secondary analyses of a study of 16,608 menopausal women in good health by the US government known as the Women’s Health Initiative.
Menopausal woman who got lung cancer and followed hormonal treatment had a 61 percent higher chance of dying from the disease than other women in the study.
Republican US lawmakers on Friday criticized US President Joe Biden’s administration after sanctioned Chinese telecoms equipment giant Huawei unveiled a laptop this week powered by an Intel artificial intelligence (AI) chip. The US placed Huawei on a trade restriction list in 2019 for contravening Iran sanctions, part of a broader effort to hobble Beijing’s technological advances. Placement on the list means the company’s suppliers have to seek a special, difficult-to-obtain license before shipping to it. One such license, issued by then-US president Donald Trump’s administration, has allowed Intel to ship central processors to Huawei for use in laptops since 2020. China hardliners
Conjoined twins Lori and George Schappell, who pursued separate careers, interests and relationships during lives that defied medical expectations, died this month in Pennsylvania, funeral home officials said. They were 62. The twins, listed by Guinness World Records as the oldest living conjoined twins, died on April 7 at the Hospital of the University of Pennsylvania, obituaries posted by Leibensperger Funeral Homes of Hamburg said. The cause of death was not detailed. “When we were born, the doctors didn’t think we’d make 30, but we proved them wrong,” Lori said in an interview when they turned 50, the Philadelphia Inquirer reported. The
RAMPAGE: A Palestinian man was left dead after dozens of Israeli settlers searching for a missing 14-year-old boy stormed a village in the Israeli-occupied West Bank US President Joe Biden on Friday said he expected Iran to attack Israel “sooner, rather than later” and warned Tehran not to proceed. Asked by reporters about his message to Iran, Biden simply said: “Don’t,” underscoring Washington’s commitment to defend Israel. “We are devoted to the defense of Israel. We will support Israel. We will help defend Israel and Iran will not succeed,” he said. Biden said he would not divulge secure information, but said his expectation was that an attack could come “sooner, rather than later.” Israel braced on Friday for an attack by Iran or its proxies as warnings grew of
A prominent Christian leader has allegedly been stabbed at the altar during a Mass yesterday in southwest Sydney. Bishop Mar Mari Emmanuel was saying Mass at Christ The Good Shepherd Church in Wakeley just after 7pm when a man approached him at the altar and allegedly stabbed toward his head multiple times. A live stream of the Mass shows the congregation swarm forward toward Emmanuel before it was cut off. The church leader gained prominence during the COVID-19 pandemic, amassing a large online following, Officers attached to Fairfield City police area command attended a location on Welcome Street, Wakeley following reports a number